Athira Pharma Q2 net loss $26.9M; LIFT-AD topline data expected Sept 2024

LeonaBio, Inc.

2024-Q2 EPS reported -$1.39

Cash, cash equivalents and investments were $91.8M as of June 30, 2024, down from $147.4M at Dec 31, 2023.
Net loss of $26.9M ($0.70 per share) for Q2 2024 vs. $29.6M ($0.78 per share) in Q2 2023.
R&D expenses $22.2M (up from $21.6M) driven by ATH-1105 Phase 1 trial; G&A down to $5.9M from $10.0M.
Topline data from Phase 2/3 LIFT-AD trial of fosgonimeton in Alzheimer's targeted for September 2024; full data at CTAD in October.
Phase 1 trial of oral ATH-1105 for ALS underway; first cohort completed, expected completion by year-end 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.